20/20 Biolabs, Inc.
AIDX
$0.52
$0.000.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.73% | -1.79% | 16.72% | 31.75% | 30.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.73% | -1.79% | 16.72% | 31.75% | 30.30% |
| Cost of Revenue | -4.95% | -6.67% | 3.48% | 6.54% | 14.56% |
| Gross Profit | 24.58% | 14.15% | 67.80% | 175.37% | 113.84% |
| SG&A Expenses | 4.21% | -12.88% | -29.77% | -29.68% | -0.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.42% | -17.05% | -27.48% | -22.35% | -1.05% |
| Operating Income | 7.40% | 22.59% | 41.16% | 36.82% | 10.09% |
| Income Before Tax | -22.98% | -0.93% | 32.65% | 34.78% | 7.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.98% | -0.93% | 32.65% | 34.78% | 7.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.98% | -0.93% | 32.65% | 34.78% | 7.45% |
| EBIT | 7.40% | 22.59% | 41.16% | 36.82% | 10.09% |
| EBITDA | 6.87% | 22.24% | 41.24% | 36.97% | 9.76% |
| EPS Basic | 2.75% | 17.69% | 34.75% | 35.44% | 8.38% |
| Normalized Basic EPS | 13.54% | 16.78% | 34.57% | 35.74% | 8.70% |
| EPS Diluted | 2.36% | 17.75% | 34.77% | 35.56% | 8.17% |
| Normalized Diluted EPS | 13.54% | 16.78% | 34.57% | 35.74% | 8.70% |
| Average Basic Shares Outstanding | 47.84% | 17.18% | 2.70% | 1.16% | 1.01% |
| Average Diluted Shares Outstanding | 47.84% | 17.18% | 2.70% | 1.16% | 1.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |